Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/8006

Title: Exploring and validating surrogate endpoints in colorectal cancer
Authors: BURZYKOWSKI, Tomasz
Yothers, Greg
Sakamoto, Junichi
Sargent, Dan
Issue Date: 2008
Publisher: SPRINGER
Citation: LIFETIME DATA ANALYSIS, 14(1). p. 54-64
Abstract: Sargent et al (J Clin Oncol 23: 8664-8670, 2005) concluded that 3-year disease-free survival (DFS) can be considered a valid surrogate (replacement) endpoint for 5-year overall survival (OS) in clinical trials of adjuvant chemotherapy for colorectal cancer. We address the question whether the conclusion holds for trials involving other classes of treatments than those considered by Sargent et al. Additionally, we assess if the 3-year cutpoint is an optimal one. To this aim, we investigate whether the results reported by Sargent et al. could have been used to predict treatment effects in three centrally randomized adjuvant colorectal cancer trials performed by the Japanese Foundation for Multidisciplinary Treatment for Cancer (JFMTC) (Sakamoto et al. J Clin Oncol 22:484-492, 2004). Our analysis supports the conclusion of Sargent et al. and shows that using DFS at 2 or 3 years would be the best option for the prediction of OS at 5 years.
Notes: Hasselt Univ, Ctr Stat, B-3590 Diepenbeek, Belgium. MSOURCE Med Dev, Warsaw, Poland. IDDI, Louvain, Belgium. NSABP, Ctr Biostat, Pittsburgh, PA USA. Nagoya Univ, Grad Sch Med, Nagoya, Aichi, Japan. Mayo Clin, Coll Med, Rochester, MN USA.Burzykowski, T, Hasselt Univ, Ctr Stat, Agoralaan D, B-3590 Diepenbeek, Belgium.tomasz.burzykowski@uhasselt.be
URI: http://hdl.handle.net/1942/8006
Link to publication: http/dx.doi.org/10.1007/s10985-007-9079-4
ISI #: 000252945100008
ISSN: 1380-7870
Category: A1
Type: Journal Contribution
Validation: ecoom, 2009
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Postprint131 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.